Urshila Durani

1.4k total citations
63 papers, 765 citations indexed

About

Urshila Durani is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Urshila Durani has authored 63 papers receiving a total of 765 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 11 papers in Hematology and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Urshila Durani's work include Lymphoma Diagnosis and Treatment (10 papers), CAR-T cell therapy research (9 papers) and Diversity and Career in Medicine (6 papers). Urshila Durani is often cited by papers focused on Lymphoma Diagnosis and Treatment (10 papers), CAR-T cell therapy research (9 papers) and Diversity and Career in Medicine (6 papers). Urshila Durani collaborates with scholars based in United States, United Arab Emirates and Pakistan. Urshila Durani's co-authors include Ronald S. Go, Ariela L. Marshall, Narjust Duma, Aneel A. Ashrani, Nilay D. Shah, Adam C. Bartley, Irbaz Bin Riaz, Rajiv K. Pruthi, Jason N. Barreto and Pritish K. Tosh and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Urshila Durani

52 papers receiving 751 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Urshila Durani United States 15 233 220 152 147 119 63 765
Elizabeth Kagan Arleo United States 19 294 1.3× 213 1.0× 154 1.0× 84 0.6× 182 1.5× 68 1.1k
Gina M. Badalato United States 18 155 0.7× 127 0.6× 290 1.9× 49 0.3× 139 1.2× 86 928
Tullika Garg United States 15 84 0.4× 160 0.7× 162 1.1× 87 0.6× 34 0.3× 43 726
Alexander Small United States 17 68 0.3× 137 0.6× 459 3.0× 75 0.5× 26 0.2× 74 865
Nicola Pavan Italy 21 193 0.8× 456 2.1× 678 4.5× 79 0.5× 28 0.2× 115 1.5k
Simple D. Singh United States 16 102 0.4× 340 1.5× 102 0.7× 39 0.3× 12 0.1× 27 759
Caroline Schenkel United States 13 340 1.5× 452 2.1× 123 0.8× 81 0.6× 24 0.2× 36 1.0k
Richard F. LeBlond United States 9 126 0.5× 46 0.2× 142 0.9× 270 1.8× 21 0.2× 14 731
Naomi Y. Ko United States 17 147 0.6× 526 2.4× 110 0.7× 66 0.4× 11 0.1× 82 942
Alberto Abrate Italy 18 113 0.5× 386 1.8× 529 3.5× 36 0.2× 21 0.2× 38 1.1k

Countries citing papers authored by Urshila Durani

Since Specialization
Citations

This map shows the geographic impact of Urshila Durani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Urshila Durani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Urshila Durani more than expected).

Fields of papers citing papers by Urshila Durani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Urshila Durani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Urshila Durani. The network helps show where Urshila Durani may publish in the future.

Co-authorship network of co-authors of Urshila Durani

This figure shows the co-authorship network connecting the top 25 collaborators of Urshila Durani. A scholar is included among the top collaborators of Urshila Durani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Urshila Durani. Urshila Durani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sridharan, Meera, Ronald S. Go, Ann M. Moyer, et al.. (2025). Clinical Outcomes and Treatment Strategies of Adult Transplant‐Associated Thrombotic Microangiopathy: External Validation of Harmonizing Definitions and High‐Risk Criteria. American Journal of Hematology. 100(5). 830–839. 3 indexed citations
2.
3.
Baranwal, Anmol, Mohamed A. Kharfan‐Dabaja, Ernesto Ayala, et al.. (2024). Surrogates of Endothelial Injury Predict Survival After Post-transplant Cyclophosphamide. Transplantation and Cellular Therapy. 31(1). 16.e1–16.e9.
4.
Bansal, Radhika, Monica Shaw, Arushi Khurana, et al.. (2024). Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy. Blood. 144(Supplement 1). 2274–2274. 1 indexed citations
5.
Bansal, Radhika, Hassan B. Alkhateeb, Stephen M. Ansell, et al.. (2024). Metformin and cytokine release syndrome after immune effector cell therapy.. Journal of Clinical Oncology. 42(16_suppl). e14535–e14535.
6.
Porrata, Luis F., Stephen M. Ansell, Ivana N. Micallef, et al.. (2024). Day 100 Recovery of Absolute Number of Inhibitory KIR2DL2 and Activating NKp30 Natural Killer Cells Predicts Survival Post-Autologous Stem Cell Transplantation in Lymphomas. Biomedicines. 12(8). 1808–1808. 1 indexed citations
7.
Leung, Nelson, Hassan B. Alkhateeb, Suheil Albert Atallah‐Yunes, et al.. (2024). Outcomes of patients who received CAR T cell therapy and developed IEC-HS treated with cytokine directed therapy.. Journal of Clinical Oncology. 42(16_suppl). 7516–7516.
8.
Porrata, Luis F., Stephen M. Ansell, Ivana N. Micallef, et al.. (2023). Day 100 Natural Killer Cell/CD14+HLA‐DRDIM ratio and survival in lymphoma post‐autologous peripheral blood hematopoietic stem cell transplantation. Clinical Transplantation. 38(1). e15211–e15211. 1 indexed citations
9.
Baranwal, Anmol, Khaled Ali, Mohamed A. Kharfan‐Dabaja, et al.. (2023). Surrogates of Endothelial Injury Predict Non-Relapse Mortality Among Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis. Transplantation and Cellular Therapy. 29(2). S9–S10. 1 indexed citations
10.
11.
Lee, Minji K., Urshila Durani, Nan Zhang, et al.. (2023). Relationships Among Health Insurance Literacy, Financial Toxicity, and Sociodemographic Factors in Patients With Cancer. JCO Oncology Practice. 19(10). 888–898. 7 indexed citations
12.
Banerjee, Rahul, Amar H. Kelkar, Urshila Durani, et al.. (2023). Demographics, Motivations, and Experiences of Participants in Transplantation or Cellular Therapy Fellowships. Transplantation and Cellular Therapy. 29(6). 394.e1–394.e7. 1 indexed citations
13.
Durani, Urshila, Ajay Major, Ana I. Velázquez, et al.. (2022). Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment. JCO Oncology Practice. 18(4). e586–e599. 8 indexed citations
14.
Major, Ajay, et al.. (2022). Frontline polatuzumab vedotin for diffuse large B‐cell lymphoma: A survey of clinician impressions. SHILAP Revista de lepidopterología. 3(3). 930–935. 3 indexed citations
15.
Durani, Urshila, et al.. (2022). The forgotten survivor: A comprehensive review on Non‐Hodgkin lymphoma survivorship. American Journal of Hematology. 97(12). 1627–1637. 6 indexed citations
16.
Durani, Urshila, Daniela Stan, Charles L. Loprinzi, et al.. (2022). Financial hardship in breast cancer survivors: a prospective analysis of change in financial concerns over time. Supportive Care in Cancer. 31(1). 62–62. 5 indexed citations
17.
Yadav, Siddhartha, Irbaz Bin Riaz, Hao Xie, et al.. (2019). Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century. Cancer. 126(1). 26–36. 90 indexed citations
18.
Duma, Narjust, Urshila Durani, Jonathan Inselman, et al.. (2019). Exploring sex differences in small cell lung cancer: Is this a hormonal issue?. Journal of Clinical Oncology. 37(15_suppl). e20077–e20077. 3 indexed citations
19.
Durani, Urshila & William J. Hogan. (2019). Emergencies in haematology: tumour lysis syndrome. British Journal of Haematology. 188(4). 494–500. 20 indexed citations
20.
Durani, Urshila & Ronald S. Go. (2016). In-Hospital Outcomes of Neutropenic Fever: A Study Using the National Inpatient Sample, Years 2009-2013. Blood. 128(22). 4762–4762.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elizabeth Kagan Arleo Breakdown of academic impact, for papers by Gina M. Badalato Breakdown of academic impact, for papers by Tullika Garg Breakdown of academic impact, for papers by Alexander Small Breakdown of academic impact, for papers by Nicola Pavan Breakdown of academic impact, for papers by Simple D. Singh Breakdown of academic impact, for papers by Caroline Schenkel Breakdown of academic impact, for papers by Richard F. LeBlond Breakdown of academic impact, for papers by Naomi Y. Ko Breakdown of academic impact, for papers by Alberto Abrate
Rankless by CCL
2026